Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
January 04 2022 - 9:00AM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced the appointment of Elizabeth Yeu, M.D. to its Board of
Directors. Dr. Yeu will continue to serve as Tarsus’ Chief Medical
Advisor. As part of her Board appointment, she will join the
Science and Technology Committee, which provides strategic
direction on external and internal innovation and pipeline
opportunities. With over 20 years of broad eye care experience, Dr.
Yeu brings proven clinical leadership to the Tarsus Board.
“We are delighted to have Dr. Yeu join our Board of
Directors during a pivotal time for the company as we approach the
potential commercialization of TP-03, our lead investigational
product for the treatment of Demodex blepharitis,” said Bobak
Azamian, M.D., Ph.D., President and Chief Executive Officer of
Tarsus. “Dr. Yeu is a prominent and well-respected thought leader
and clinician and has a deep understanding of the unmet needs in
eye care. I am grateful for her expertise and guidance as we plan
for the company’s growth and pipeline expansion.”
Dr. Yeu brings a wealth of eye care experience to
the Tarsus Board, having authored hundreds of articles and
conducted numerous lectures on subjects such as refractive cataract
surgery, anterior segment reconstruction, and external ocular
disease management. In addition to serving as Tarsus’ Chief Medical
Advisor since August 2020, Dr. Yeu is a partner and practicing
ophthalmologist at Virginia Eye Consultants and Medical Director at
Virginia Surgery Center. She also provides guidance and governance
across several national medical boards and committees, including as
an examiner for the American Board of Ophthalmology and as the
Chair of the Cataract Section of Ophthalmic News & Education
(ONE) Network for the American Academy of Ophthalmology (AAO). Dr.
Yeu is also an Executive Committee member and the current Secretary
for the American Society of Cataract and Refractive Surgery (ASCRS)
and, in 2023, she will become the ASCRS President.
“Tarsus has made remarkable progress in advancing
TP-03 for the treatment of Demodex blepharitis, and I am honored to
have the opportunity to broaden my responsibility by joining the
Board of Directors and the Science and Technology Committee,” said
Dr. Yeu. “The company is at the forefront of developing multiple
innovative therapeutics that have the potential to make a
meaningful difference in many patients’ daily lives, and I am
delighted to contribute towards the strategic path of the
company.”
Dr. Yeu currently serves on the Boards of Directors
of STAAR Surgical, Ocular Science, and the Virginia Eye Foundation.
She also serves as an Executive Committee Member of CVP Physicians,
Mid Atlantic. Dr. Yeu earned her M.D. through an accelerated and
combined undergraduate/medical school program at the University of
Florida College of Medicine. She completed her ophthalmology
residency at Rush University Medical Center in Chicago, where she
served as Chief Resident. She then completed a fellowship in
cornea, anterior segment, and refractive surgery at the Cullen Eye
Institute, Baylor College of Medicine, where she also served as an
Assistant Professor. She continues to train residents as an
Assistant Professor at the Eastern Virginia Medical School.
About Tarsus Pharmaceuticals,
Inc.Tarsus Pharmaceuticals, Inc. applies proven science
and new technology to revolutionize treatment for patients,
starting with eye care. It is advancing its pipeline to address
several diseases with high unmet need across a range of therapeutic
categories, including eye care, dermatology, and infectious disease
prevention. The company is studying two investigational medicines
in clinical trials. Its lead product candidate, TP-03, is a novel
therapeutic being studied in a second Phase 3 pivotal trial for the
treatment of Demodex blepharitis. TP-03 is also being developed for
the treatment of Meibomian Gland Disease. In addition, Tarsus is
developing TP-05, an oral, non-vaccine therapeutic for the
prevention of Lyme disease, which is currently being studied in a
Phase 1 clinical trial.
Forward Looking Statements
Statements in this press release about future expectations, plans
and prospects, as well as any other statements regarding matters
that are not historical facts, may constitute “forward-looking
statements.” These statements include statements regarding Tarsus’
plans for and the anticipated benefits of its product candidates,
including TP-03, the benefits and value added by the new director,
the timing, objectives and results of the clinical trials and
anticipated regulatory and development milestones, including the
potential commercialization of the Company’s products, and the
quotations of Tarsus’ management and board members. The words,
without limitation, “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these or
similar identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors and are detailed from time to time in
the reports Tarsus files with the Securities and Exchange
Commission, including Tarsus’ Form 10-K for the year ended December
31, 2020 filed on March 31, 2021 and the most recent Form 10-Q for
the quarter ended September 30, 2021 filed with the SEC on November
10, 2021, which Tarsus incorporates by reference into this press
release, copies of which are posted on its website and are
available from Tarsus without charge. However, new risk factors and
uncertainties may emerge from time to time, and it is not possible
to predict all risk factors and uncertainties. Accordingly, readers
are cautioned not to place undue reliance on these forward-looking
statements. Any forward-looking statements contained in this press
release are based on the current expectations of Tarsus’ management
team and speak only as of the date hereof, and Tarsus specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact:SuJin Oh Shop
PR(917) 841-5213sujin@shop-pr.com
Investor Contact:David
Nakasone Head of
Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024